Maria Serena Roca

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Alfredo Budillon · 5 shared papers, 2022–2026 · strength 0.87
   • Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575↗
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
   • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
2. Antonio Avallone · 3 shared papers, 2022–2024 · strength 0.42
   • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
   • Paper HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartm… DOI 10.1186/s13046-022-02295-4↗
   • Paper Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer ste… DOI 10.1186/s13046-022-02324-2↗
3. Tero A. Aittokallio · 1 shared paper, 2026 · strength 0.26
   • Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575↗
4. Veronica Barile · 1 shared paper, 2026 · strength 0.26
   • Paper Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring te… DOI 10.1016/j.biopha.2026.119575↗
5. Carla Mottini · 1 shared paper, 2024 · strength 0.20
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
6. Damiano D. Caputo · 1 shared paper, 2024 · strength 0.20
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
7. Giovanni Blandino · 1 shared paper, 2024 · strength 0.20
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
8. Giulio Caracciolo · 1 shared paper, 2024 · strength 0.20
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
9. Giulia Piaggio · 1 shared paper, 2024 · strength 0.20
   • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
10. Christian P. Pilarsky · 1 shared paper, 2024 · strength 0.20
    • Paper The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promi… DOI 10.1186/s13046-024-03117-5↗
11. Francesca Foschini · 1 shared paper, 2024 · strength 0.16
    • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
12. Marina Macchini · 1 shared paper, 2024 · strength 0.16
    • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
13. Claudia Fuchs · 1 shared paper, 2024 · strength 0.16
    • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
14. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.16
    • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗
15. Michele Reni · 1 shared paper, 2024 · strength 0.16
    • Paper Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in un… DOI 10.1186/s12885-024-12936-w↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.